Global Hematopoietic Stem Cell Transplantation Market Overview
Hematopoietic Stem Cell Transplantation Market Size was valued at USD 2.8 Billion in 2022. The Hematopoietic Stem Cell Transplantation Market industry is projected to grow from USD 3.1 Billion in 2023 to USD 7.7 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.90% during the forecast period (2024 - 2032). The increasing incidence of hematological disorders, expanding healthcare expenditure, a rising elderly population susceptible to diseases due to weakened immune systems, and the surge in research and development efforts are market drivers for the Hematopoietic Stem Cell Transplantation Market.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Hematopoietic Stem Cell Transplantation Market Trends
- Increasing incidence of leukemia and lymphoproliferative disorders and the increasing geriatric population are driving the market growth
Market CAGR for Hematopoietic Stem Cell Transplantation is driven by the increasing incidence of leukemia and lymphoproliferative disorders and the increasing geriatric population. The market is being driven by the increasing incidence of leukemia and lymphoproliferative disorders, alongside heightened research and development efforts by biotechnology firms. According to data released by the Leukemia & Lymphoma Society (LLS) in 2021, approximately 61,090 individuals were projected to receive a leukemia diagnosis in 2021. Furthermore, the LLS reported that roughly 397,501 individuals were either living with leukemia or in remission from the disease in the United States during the same year. Additionally, it was noted that approximately every 3 minutes, one person in the United States was diagnosed with leukemia, lymphoma, or myeloma. Similarly, a study titled "Rates and trends of childhood acute lymphoblastic leukemia: an epidemiology study," published in April 2021, highlighted acute lymphoblastic leukemia (ALL) as the most prevalent cancer in childhood, accounting for up to 25.0% of cancers among children under the age of 15.
The growth of the hematopoietic stem cell transplantation (HSCT) market is anticipated to be fueled by the rising elderly population in the coming years. For instance, in October 2022, data released by the World Health Organization highlighted that from 2015 to 2050, the proportion of the world's population aged over 60 is projected to nearly double, increasing from 12% to 22%. The population aged 60 years and above is expected to rise from 1 billion in 2020 to 1.4 billion. By 2050, the population of individuals aged 60 and older is forecasted to double to 2.1 billion. Additionally, the number of individuals aged 80 years or older is estimated to triple between 2020 and 2050, reaching 426 million. As a result, it is anticipated that throughout the projection period, demand for the Hematopoietic Stem Cell Transplantation Market will increase due to the increasing incidence of leukemia and lymphoproliferative disorders and the increasing geriatric population. Thus, driving the Hematopoietic Stem Cell Transplantation Market revenue.
Hematopoietic Stem Cell Transplantation Market Segment Insights
Hematopoietic Stem Cell Transplantation Market Transplant Type Insights
The Hematopoietic Stem Cell Transplantation Market segmentation, based on Transplant Type, includes Allogeneic and Autologous. The autologous segment dominated the market, accounting for 58% of market revenue. The incidence of developing cancer rises significantly as individuals age, largely due to the accumulation of risks associated with aging. Factors contributing to the overall increase in cancer risk include aging itself, the adoption of Western lifestyles, unhealthy dietary habits such as consuming dairy products, processed foods, and food additives, non-vegetarian diets, exposure to chemical pollutants, sedentary lifestyles, and other related factors like constipation. Consequently, there has been a notable surge in demand for autologous hematopoietic stem cell transplantation, particularly for the treatment of specific cancer types.
Figure 1: Hematopoietic Stem Cell Transplantation Market, by Transplant Type, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Hematopoietic Stem Cell Transplantation Market Indication Insights
The Hematopoietic Stem Cell Transplantation Market segmentation, based on Indication, includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, and Other Non-Malignant Disorders. The acute myeloid leukemia segment dominated the market, accounting for 58% of market revenue. As HSCT techniques and supportive care measures continue to advance, there has been a notable enhancement in the survival rates of AML patients undergoing transplantation. In 2020, an estimated 73,168 people were living with acute myeloid leukemia in the United States. This positive outcome has fostered confidence among healthcare professionals and patients alike, leading to a greater acceptance and utilization of HSCT as a viable treatment approach.
Hematopoietic Stem Cell Transplantation Market Application Insights
The Hematopoietic Stem Cell Transplantation Market segmentation, based on Application, includes Bone Marrow Transplant, Peripheral Blood Stem Cells Transplant, and Cord Blood Transplant. The bone marrow transplant segment dominated the market, accounting for 60% of market revenue. The segment's growth is expected to be further fueled by increasing initiatives from both public and private sectors towards bone marrow transplants. For instance, in September 2022, QUINT founders contributed approximately USD 16.0 million to establish the QUINT Bone Marrow Transplant Centre in Dubai. Furthermore, the demonstrated high efficacy and benefits of bone marrow transplants in treating acute myeloid leukemia are driving segment expansion. For instance, a study conducted by the University of California San Francisco in 2021 revealed that allogeneic transplantation, which involves using stem cells or bone marrow from a tissue-matched sibling or unrelated donor, yields cure rates of approximately 50.0% to 60.0% in patients with intermediate-risk acute myeloid leukemia.
Hematopoietic Stem Cell Transplantation Market Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The anticipated expansion of the Hematopoietic Stem Cell Transplantation market in North America can be attributed to several key factors. The growth rate of the hematopoietic stem cell transplant market is significantly influenced by the increase in healthcare expenditure, which facilitates the development of the market's infrastructure. According to the CDC, healthcare spending in the United States expanded by 4.1% to reach $4.5 trillion in 2022, demonstrating a faster growth rate compared to the 3.2% increase in 2021, albeit much slower than the 10.6% rate recorded in 2020. The efforts of various government organizations to enhance healthcare infrastructure through increased funding will further shape market dynamics. Factors such as key product launches, a high concentration of market players or manufacturers, and acquisitions and partnerships among major players, coupled with the increasing presence in the United States, are driving the growth of the hematopoietic stem cell transplantation market in the country. For example, data from the Leukemia and Lymphoma Society's Facts and Statistics revealed that approximately 90,390 individuals in the United States were expected to receive lymphoma diagnoses in 2021, comprising 8,830 cases of Hodgkin Lymphoma and 81,560 cases of Non-Hodgkin Lymphoma.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: Hematopoietic Stem Cell Transplantation Market Share By Region 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Hematopoietic Stem Cell Transplantation Market accounts for the second-largest market share, as Europe possesses a highly developed and sophisticated healthcare infrastructure featuring specialized transplant centers and comprehensive cancer facilities. These establishments offer access to cutting-edge technology, expert personnel, and essential resources essential for the successful execution of HSCT procedures. Germany stands out for its robust healthcare system, particularly in terms of infrastructure, hospital capacity, and skilled workforce. Approximately one out of every six jobs in Germany is associated with the healthcare sector, contributing significantly to the country's economic landscape with an estimated economic footprint of EUR 775 billion (USD 883 billion), representing approximately 12 percent of Germany's GDP. In 2022, the gross value added by the healthcare industry in Germany amounted to EUR 439.6 billion. This economic aspect incentivizes further investment in healthcare infrastructure, research, and development, fostering innovation and advancement in HSCT technologies and procedures. Further, the German Hematopoietic Stem Cell Transplantation Market held the largest market share, and the UK Hematopoietic Stem Cell Transplantation Market was the fastest-growing market in the European region.
The Asia-Pacific Hematopoietic Stem Cell Transplantation Market is expected to grow at the fastest CAGR from 2024 to 2032. The Asia-Pacific region is poised to experience significant growth driven by various factors, including increased government initiatives to promote healthcare, rising health consciousness among the populace, and growing demand for advanced medical technologies, particularly in skincare. The region's large population pool and escalating demand for high-quality healthcare further contribute to this growth trajectory. Notably, health expenditure in China has surged from under 500 billion yuan in 2000 to over 6.5 trillion yuan in 2019. The Chinese government has actively supported the expansion of the healthcare market through policy documents and development blueprints, with the "Healthy China 2030" initiative being a key focus. One of the primary objectives of this initiative is to elevate the healthcare service industry to a value of RMB 16 trillion (approximately US$2.4 trillion) by 2030. Japan, as the second-largest contributor to the Contingency Fund for Emergencies (CFE) with a donation of US$ 32 million, stands out as a significant supporter of the WHO Health Emergencies Programme (WHE) during humanitarian crises. Since 2016, Japan has provided a total of US$ 113 million to WHE, including US$ 60 million for Syria and US$ 3 million for Yemen. In April 2022, Japan further demonstrated its commitment by signing an agreement to provide US$ 3.1 million to assist the WHO in addressing infectious diseases, including COVID-19, in Ukraine and neighboring countries. Japan's commitment to supporting the WHO and other health organizations in addressing emergencies and infectious diseases can lead to improvements in healthcare infrastructure, including facilities for HSCT procedures. This enhancement in infrastructure can facilitate the delivery of HSCT services to patients in need. Moreover, China’s Hematopoietic Stem Cell Transplantation Market held the largest market share, and the Indian Hematopoietic Stem Cell Transplantation Market was the fastest-growing market in the Asia-Pacific region.
Hematopoietic Stem Cell Transplantation Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the Hematopoietic Stem Cell Transplantation market grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Hematopoietic Stem Cell Transplantation industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Hematopoietic Stem Cell Transplantation industry to benefit clients and increase the market sector. In recent years, the Hematopoietic Stem Cell Transplantation industry has offered some of the most significant advantages to the medical field and patients alike. Major players in the Hematopoietic Stem Cell Transplantation Market, including Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Sanofi, Taiga, Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics are attempting to increase market demand by investing in research and development operations.
Lonza Group Ltd (Lonza) is a company specializing in contract manufacturing and development solutions. Its services encompass commercial mammalian and microbial manufacturing, clinical development, and manufacturing. Lonza also provides high-potential active pharmaceutical ingredients, cell and gene therapy capabilities, advanced intermediates, oral drug product development services, cell-culture modeling, genome editing, endotoxin products, and research media and testing products. The company offers solutions for health and well-being, microbial and hygiene control, and composites and material protection. Lonza caters to the biotechnology, pharmaceutical, academic, and government research industries, as well as manufacturers of health and consumer products, and formulators and service companies. It operates manufacturing and R&D facilities across Asia, Europe, and the Americas, with its headquarters situated in Basel, Switzerland. In November 2022, Lonza introduced an innovative capsule solution for enteric drug administration known as the Capsugel Enprotect capsule. These capsules do not dissolve in the stomach, releasing their contents only in the intestine. By eliminating the need for extra capsule coating or sealing, Capsugel Enprotect capsules streamline the medicinal product production process significantly.
Taiga Biotechnologies Inc (Taiga Biotech) is a biopharmaceutical company specializing in the development of protein and cellular therapies. Their focus lies in creating therapies for a range of diseases, including cancers and infectious diseases. The company's pipeline includes programs such as stem cell therapy and target-specific T-cells, aimed at addressing conditions such as HIV, influenza, and various hematologic disorders. Taiga Biotech provides innovative technologies for hematopoietic stem cells (HSCs), offering diverse applications in drug discovery, screening, and product development. Their research spans clinical areas such as red blood cell pharming, vaccine adjuvants, cell therapies, and bone marrow engraftment enhancement. Leveraging natural defense mechanisms, the company is dedicated to combating infectious diseases and various forms of cancer, encompassing both hematological cancers and solid tumors. Taiga Biotech is headquartered in Aurora, Colorado, USA.
Key companies in the Hematopoietic Stem Cell Transplantation Market include.
Hematopoietic Stem Cell Transplantation Industry Developments
May 2022: Priothera obtained clearance from the United States Food and Drug Administration for an investigational new drug (IND) to initiate a Phase 2b/3 study involving mocravimod in Acute Myeloid Leukemia (AML) Patients undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT).
October 2022: Regen BioPharma, Inc. announced the filing of a provisional patent application to the US Patent and Trademark Office under the title "Enhancement of T Cell Homing to Tumors through Augmentation of Chemokine Responsiveness and Activation Dependent Chemokine Secretion.
Hematopoietic Stem Cell Transplantation Market Segmentation
Hematopoietic Stem Cell Transplantation Market Transplant Type Outlook
Hematopoietic Stem Cell Transplantation Market Indication Outlook
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- Multiple Myeloma
- Other Non-Malignant Disorders
Hematopoietic Stem Cell Transplantation Market Application Outlook
- Bone Marrow Transplant
- Peripheral Blood Stem Cells Transplant
- Cord Blood Transplant
Hematopoietic Stem Cell Transplantation Market Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
Hematopoietic Stem Cell Transplantation Market Report Scope
| Report Attribute/Metric |
Details |
| Market Size 2022 |
USD 2.8 Billion |
| Market Size 2023 |
USD 3.1 Billion |
| Market Size 2032 |
USD 7.7 Billion |
| Compound Annual Growth Rate (CAGR) |
11.90% (2024-2032) |
| Base Year |
2023 |
| Market Forecast Period |
2024-2032 |
| Historical Data |
2019-2022 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Transplant Type, Indication, Application, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Sanofi, Taiga, Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics |
| Key Market Opportunities |
· Advancements in HSCT techniques |
| Key Market Dynamics |
· Increasing prevalence of hematological disorders |
Frequently Asked Questions (FAQ) :
The Hematopoietic Stem Cell Transplantation Market size was valued at USD 3.1 Billion in 2023.
The Hematopoietic Stem Cell Transplantation Market is projected to grow at a CAGR of 11.90% during the forecast period, 2024-2032.
North America had the largest share of the market.
The key players in the market are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Sanofi, Taiga, Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics.
The Autologous segment dominated the market in 2023.
The Bone Marrow Transplant segment had the largest share of the market.
